Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2
Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 Uses, Dosage, Side Effects, Food Interaction and all others data.
Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
| Trade Name | Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 |
| Generic | Olinvacimab |
| Olinvacimab Other Names | Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2, Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer, Olinvacimab, Tanibirumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2
